





۵

Educational Objectives

At the conclusion of this symposium, participants will be able to:

· Describe the role of CAR T- cell therapy and bispecifics in treating blood cancer

Meeting space has been assigned to provide a Symposia supported by The Leukemia & Lymphoma Society during the Oncology Nursing Society's (ONS) 49th Annual Congress, April 24 – April 28, 2024 in Washington, DC. The Oncology Nursing Society's assignment of

meeting space does not imply product endorsement.

- Apply knowledge of communication strategies, streamlined patient assessment, disparities in care, and strategies for multidisciplinary teams to improve patientcentered care
- Explain data surrounding CAR T-cell and bispecific therapies including their proper application, efficacy, and adverse events, and resources to support patients and their caregivers
- Optimize patient assessment to ensure effective, individualized patient care including implementation of bridging therapy when indicated
- Utilize appropriate tools to properly assess risk for progression and response to cellular therapies



LEUKEMIA & LYMPHOMA SOCIETY

CE Designation



۵

Nursing Continuing Professional Development Contact Hours

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care of the Pediatric Hematology and Oncology Patient (CPHON), Cellular Collection, Preparative Regimens, and Infusion (BMTCN), Early Posttransplant Management and Education (BMTCN), Foundations of Transplant (BMTCN), Late Post-Transplant Management and Education (BMTCN), Oncologic Emergencies (OCN, CPHON, AOCNP), Professional Practice/Performance (BMTCN, AOCNP), Psychosocial Dimensions of Care (AOCNP, CPHON, ONC, CBCN), Quality of Life (BMTCN), Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP), Transplant Process and Infusion (BMTCN), Treatment (OCN, CBCN, AOCNP, CPHON).

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Nurse Practitioner Continuing Education


This education activity will be submitted to the American Association of Nurse Practitioners® for approval of up to XX contact hours of accredited education


Social Worker Continuing Education


The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.5 clinical continuing education credits.


The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.5 clinical CE contact hours for this activity.












Webcasts, Videos, Podcasts, booklets:	
www.LLS.org/Webcasts	CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY
www.LLS.org/EducationVideos	TERATURAT On the pages To Standards
www.LLS.org/Podcast	Channer 44, Binner Green Channer 44, Binner Green Channer 44, Binner Green Channer 44, Binner Green Channer 54, Binner Streen
· · · · · · · · · · · · · · · · · · ·	Cambridge and Annual Annu
www.LLS.org/Booklets	Landon range from Manage Sementalization Manage Sementalization The mean semantic for balance approximation polynomia biological approximation polynomia biological
www.LLS.org/CARTtherapy	Type of Character Type of Character Type of Character Type of Character
	Ding Limity + Evolution for a set of the control of the control of the set of the control of the
Support Resources	Dag Tangan Banaran Banaran Katar antaka Katar antaka
Financial Assistance: <u>www.LLS.org/Finances</u>	
- Urgent Need	
- Patient Aid	LEUKEMA 6 SYCREPY
- Travel Assistance	
Other Support: <u>www.LLS.org/Support</u>	
- LLS Regions	
- Online Weekly Chats Facilitated by Oncology SW	
- LLS Community Social Media Platform	CANCER AND
- First Connection Peer to Peer Program	YOUR FINANCES
· ·	



Faculty

Jessica R. Kassay-McAllister, DNP, RN, AGACNP-BC

Oncology APP Manager Division of Hematology/Oncology Cellular Therapy/Stem Cell Transplant Program, Effector Cell NP UVA School of Nursing Clinical Faculty University of Virginia Comprehensive Cancer Center Charlottesville, VA

Krithika Shanmugasundaram, MD


Assistant Professor of Medicine, Division of Hematology/Oncology University of Virginia Comprehensive Cancer Center Charlottesville, VA


Dan T. Vogl, MD, MSCE


Director, Abramson Cancer Center Clinical Research Unit Associate Professor of Medicine Perelman School of Medicine University of Pennsylvania Philadelphia, PA




•	Faculty Disclosures
	Jessica Kassay-McAllister DNP, RN, AGACNP-BC, has no financial relationships with ineligible companies.
	Krithika Shanmugasundaram, MD, has no financial relationships with ineligible companies.
	Dan T. Vogl, MD, MSCE, has financial relationships with the following companies: Advisory Board/Consultant: AbbVie, CSL Behring, Genentech, Takeda Research/Grant: Active Biotech, Takeda
	LEUKEMIA & LYMPHOMA SOCIETY














۵ Learning Objectives Describe the role of CAR T- cell therapy and bispecifics in treating blood cancer Apply knowledge of communication strategies, streamlined patient • assessment, disparities in care, and strategies for multidisciplinary teams to improve patient-centered care Explain data surrounding CAR T-cell and bispecific therapies including • their proper application, efficacy, and adverse events, and resources to support patients and their caregivers Optimize patient assessment to ensure effective, individualized patient • care including implementation of bridging therapy when indicated Utilize appropriate tools to properly assess risk for progression and response to cellular therapies LEUKEMIA & LYMPHOMA SOCIETY













Indications


- ≻ B-ALL
- Multiple Myeloma
- > NHL
 - > DLBCL
 - Follicular lymphoma
 - Mantle Cell Lymphoma (MCL)
 - ≻ CLL

ALL IN RELAPSED/REFRACTORY SETTING












<section-header><section-header>







Long-Term Survival With Axi-Cel in Patients with Refractory Large B-Cell Lymphoma














<section-header><section-header><section-header><section-header><section-header><section-header><section-header>



























Polling Question CRS is characterized by extreme inflammatory response triggered by increased IL-2, IL-6, tumor necrosis factor-alpha and other inflammatory cytokines. _____ is a required initial finding to diagnose CRS of any grade. A. Rash B. Neutropenia C. Fever D. Hypotension





























ICANS – Encephalopathic State


Can range from mild tremors to seizures and loss of consciousness


Early signs are diminished attention, mild aphasia, and/or handwriting changes














ICE Score ۵ ICE Question **Points** Orientation Year, Month, city, hospital 4 Naming Ability to name 3 objects 3 2 Following commands Follow 2 simple commands Count backwards from 100 by 10 Attention 1 Writing Write a simple sentence 1 LEUKEMIA & LYMPHOMA SOCIETY

-9	3-6	0-2	0 – Unable to perform ICE
	9	9 3-6	9 3-6 0-2

ICANS Grading


Neurotoxicity Domain	Grade 1	Grade 2	Grade 3	Grade 4
ICE score	7-9	3-6	0-2	0 – Unable to perform ICE
Depressed level of consciousness	Spontaneous awakening	Awakens to voice	Awakens only to tactile stimulus	Not arousable to tactile stimulus, Coma



Neurotoxicity Domain	Grade 1	Grade 2	Grade 3	Grade 4
ICE score	7-9	3-6	0-2	0 – Unable to perform ICE
Depressed level of consciousness	Spontaneous awakening	Awakens to voice	Awakens only to tactile stimulus	Not arousable to tactile stimulus, Coma
Seizure	N/A	N/A	Any clinical or non convulsive seizures that resolve with Intvn	Prolonged seizure >5 mins. EEG activity –not resolving with Intvn

ICANS Grading

Neurotoxicity Domain	Grade 1	Grade 2	Grade 3	Grade 4
ICE score	7-9	3-6	0-2	0 – Unable to perform ICE
Depressed level of consciousness	Spontaneous awakening	Awakens to voice	Awakens only to tactile stimulus	Not arousable to tactile stimulus, Coma
Seizure	N/A	N/A	Any clinical or non convulsive seizures that resolve with Intvn	Prolonged seizure >5 mins. EEG activity –not resolving with Intvn
Motor Findings	N/A	N/A	N/A	Hemiparesis, paraperisis
Elevated ICP/Cerebral edema	N/A	N/A	Focal or Local edema on Neuro-image	Diffuse cerebrat MIA & edema integing SOCIETY



Next steps -ICANS

- > CT Head, MRI Brain as soon as possible
- Start on steroids
- Ophtho consult -> papilledema
- Neuro Onc consult

Consider

- Infection -> cultures, imaging, abx if neutropenic
- Medication/sedation-> review, decrease polypharmacy
- Delirium -> PT/OT, reorientation

LEUKEMIA & LYMPHOMA SOCIETY[®]

Common Barriers to CAR T

- Insurance
 - > ~\$300,000 to \$450,000 per product
- Caregiver
- ➤ Lodging
- Disease status



۵

Myeloma Case – Part 1

60 year-old woman with no sig PMHx, presenting with fatigue, back pain, vertebral compression fractures, anemia, hypercalcemia, monoclonal gammopathy, and bone marrow plasmacytosis



> 2017 Treatment line 1:

- > VRd with VGPR
- ➤ MEL ASCT with CR
- > Len maintenance x2 years

> 2019 Treatment line 2:

Dara/carfilzomib/dex with PR and progression

> 2020 Treatment line 3:

 elotuzumab/pomalidomide/dex with PR and progression


2021 Treatment line 4:

Cyclophosphamide/bortezomib/dex with PD


> 2021 Assessed for ide-cel


- > T cell apheresis
- Bridging therapy with selinexor/car/pom/dex
- LD chemo with fludarabine/cyclophosphamide
















Myeloma Case – Part 2

60 year-old woman with IgG lambda myeloma

- ➤ Line 1: VRd -> MEL ASCT -> Len maint
- Line 2: Dara/carfilzomib/dex
- Line 3: elotuzumab/pomalidomide/dex
- Line 4: Cyclophosphamide/bortezomib/dex

> 2021 ide-cel

- Bridging with selinexor/car/pom/dex
- Cytopenias lasting 3 months, requiring intermittent transfusions and G-CSF, then resolved
- Myeloma response: VGPR for 15 months, then progression

12/2022: teclistamab

- Admitted for step-up dosing
- Grade 2 CRS treated with tocilizumab
- Grade 1 ICANS treated with steroids
- Myeloma response sCR x1 year



75

Using Bispecific Antibodies in Clinical Care: Managing Toxicity

> Cytokine release syndrome / ICANS

- > Step-up dosing requires expertise in identifying and managing CRS and ICANS
- > Tocilizumab is an important component of the management of CRS
 - > Not mentioned in the package inserts or REMS programs
 - > Used in 36% of patients in the phase 2 trial of teclistamab

Neutropenia

- > 64% grade 3/4 with teclistamab
- Consider CMV reactivation
- Concomitant supportive G-CSF is effective

Infection risk

- Profound immune paresis: Use IVIG supplementation to maintain IgG > 400 mg/dL
- Risk of shingles: Use acyclovir or valacyclovir
- Pneumocystis pneumonia: Use TMP-SMX





•	Infection Risk					
	CAR T cells may not confer more infection risk than other MM the					
	Infection	risk on Ph	ase 3 CAF	R T studies	for MM	
		CAR T		Standard Care		
		Any Grade	Grade ≥3	Any Grade	Grade ≥3	
	CARTITUDE-4	62%	27%	71%	25%	
	KARMMA-3	58%	29%	54%	20%	
			1		1	
	San Miguel et al., N Engl J Med 2023;389:335-34 Rodriguez-Otero et al., N Engl J Med 2023;388:1002-101-	4				

77

Infection Risk ۵

- > CAR T cells may not confer more infection risk than other MM therapies
- Continuously dosed anti-BCMA bispecific antibodies have significant infection risk \triangleright






Infection Risk

- > CAR T cells may not confer more infection risk than other MM therapies
- > Continuously dosed anti-BCMA bispecific antibodies have significant infection risk

IVIG likely significantly reduces the risk of severe infection on anti-BCMA bsAb



Polling Question 5

Which premedications need to be given for myeloma bispecifics during routine outpatient administration:

- A. steroids
- B. diphenhydramine
- C. acetaminophen
- D. all of the above
- E. none of the above

Using Bispecific Antibodies: Administration and Dosing

Location

- Initial dosing should be given at a center with expertise in management of CRS
 Typically inpatient dosing, but outpatient can be considered with appropriate resources
- > Ongoing dosing can be continued in the community (outpatient, no premeds, no observation)

For teclistamab: consider q2 week dosing

- Per package insert: weekly dosing
- > Clinical trial permitted Q2 week dosing after 6 months in complete response
- Penn plan: change to Q2 week dosing at best response

>Consider outpatient rechallenge after dose interruption

- ➢ Per package insert: repeat inpatient step-up dosing (0.06→0.3→1.5) after delay of >28 days
- $\succ~$ Penn plan: outpatient single dose of 0.3 mg/kg \rightarrow 1.5 mg/kg weekly



LEUKEMIA & LYMPHOMA SOCIETY

Myeloma Case – Part 3

60 year-old woman with IgG lambda myeloma

- Line 1: VRd -> MEL ASCT -> Len maint
- Line 2: Dara/carfilzomib/dex
- Line 3: elotuzumab/pomalidomide/dex
- Line 4: Cyclophosphamide/bortezomib/dex
- ➤ Line 5: ide-cel

12/2022: teclistamab

- Myeloma response sCR x1 year
- Progressive disease with extramedullary plasmacytomas, biopsy shows no BCMA expression

12/2023: talquetamab

- Admitted for step-up dosing
- Grade 1 CRS, no ICANS
- Myeloma response: sCR ongoing @5 months
- Severe dysgeusia, mild palmar desquamation



83

Management of Talquetamab Toxicities

Oral and taste toxicities

- Dysgeusia
- > Dry mouth
- Dysphagia
- > Weight loss

> Management

- saliva substitute sprays and rinses
- dose holds & adjustments
- dietary modifications
- good oral care

Skin and nail toxicity

- Dry skin
- Hand or foot peeling
- Nail thinning and peeling
- Pruritis
- Diffuse macules and papules
- Injection site reactions

Management

- Moisturizing lotions
- Ammonium lactate for peeling
- Nail hardeners and topical vitamin E
- Ioratadine
- topical steroids

























ASTCT ICANS Grade	Management
Grade I	-Consider seizure prophylaxis with levetiracetam if not already started. -Review of medications, avoid medications that can cause CNS depression. -Swallowing assessment and aspiration precautions. -Neurocognitive assessment Q6hrs using ICE scoring system. -Neurology consult. -Consider EEG. -Consider lumbar puncture with opening pressure and samples for chemistry, cytology, virology, & culture. -Brain imaging (MRI preferred if no contraindication). Spinal MRI based on neurological findings. -For febrile patients, infectious workup per institutional guidelines. -Consider tocilizumab if concurrent CRS.
Grade 2	-Supportive care and workup per Grade I. -Consider dexamethasone IOmg IV every 6hrs or methylprednisolone equivalent. -Tocilizumab if concurrent CRS. -Consider transfer to intensive care unit.
Grade 3	-Supportive care and workup per Grade I. -Transfer to intensive care unit. -Dexamethasone 10-20mg IV every 6 hours or methylprednisolone equivalent. -High-dose methylprednisolone (1000mg/day) for focal/local edema. -Seizure control with benzodiazepines (for short-term control) and levetiracetam ± lacosamide. -If evidence of increased ICP (stage 1-2 by fundoscopy or opening pressure >20 mmHg), urgent neurology consultation to guide management. -Repeat neuroimaging if persistent grade ≥3 ICANS.
Grade 4	-Supportive care and workup per Grade I. -Transfer to intensive care unit, may need mechanical ventilation for airway protection. -High-dose methylprednisolone 1000mg/day for 3 days followed by taper. -Seizure control per Grade 3. -Management of raised ICP per neurology/neurosurgery intensive care recommendations. May use hyperosmolar therapy (mannitol/hypertonic saline), hyperventilation strategy.







۵

ASTCT Consensus Grading

	emperature ≥38°C	Temperature ≥38°C	Temperature ≥38°C With	Temperature \geq 38°C		
Hypotension No			With			
Hypotension No		With				
nypotension	one	Not requiring vasopressors	Requiring a vasopressor with or without vasopressin	Requiring multiple vasopressors (excluding vasopressin)		
·			And/or [†]			
Hypoxia No	one	Requiring low-flow nasal cannula [‡] or blow-by	Requiring high-flow nasal can- nula [‡] , facemask, nonrebreather mask, or Venturi mask	Requiring positive pressure (eg, CPAP, BiPAP, intubation and mechanical ventilation)		

Lee, D.W., et al, 2018. ASBMT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. *Biology of Blood and Marrow Transplantation*.

